|
DE69332002T2
(de)
|
1992-08-25 |
2002-12-19 |
Monsanto Co |
Hydroxyethylaminosulfonamide verwendbar als Inhibitoren retroviraler Proteasen
|
|
EP0877937B1
(en)
|
1996-01-26 |
2002-05-22 |
Virco N.V. |
Method of assessing the chemotherapy of hiv-positive patients based on the phenotypic drug sensitivity of the patient's hiv strains
|
|
US6242187B1
(en)
|
1996-01-29 |
2001-06-05 |
Virologic, Inc. |
Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
|
|
AU8897698A
(en)
*
|
1997-07-30 |
1999-02-22 |
Virologic, Inc. |
Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
|
|
WO1999051776A1
(en)
*
|
1998-04-07 |
1999-10-14 |
Southern Research Institute |
High-throughput method for screening for antiviral activity
|
|
BR9911600A
(pt)
*
|
1998-05-26 |
2001-02-13 |
Virologic Inc |
Recursos e métodos para monitoração de terapia antiretroviral inibidora de transcriptase reversa de não nucleosìdeo
|
|
US7037644B1
(en)
|
1998-05-26 |
2006-05-02 |
Virologic, Inc. |
Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
|
|
US20030148307A1
(en)
|
1998-06-19 |
2003-08-07 |
Department Of Health & Human Services, C/O Centers Of Disease Control And Prevention |
Method and kit for detecting resistance to antiviral drugs
|
|
ES2237923T3
(es)
*
|
1998-06-19 |
2005-08-01 |
The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Metodo para detectar resistencia a los medicamentos antivirales.
|
|
US6787126B1
(en)
|
1998-06-19 |
2004-09-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method and kit for detecting resistance to antiviral drugs
|
|
BR9912209A
(pt)
*
|
1998-06-24 |
2002-11-05 |
Virologic Inc |
Recursos e métodos para monitoração de terapia anti-retroviral inibidora de transcriptase reversa de nucleosìdeo e guia de decisões terapêuticas no tratamento de hiv/aids
|
|
ES2246859T3
(es)
|
1999-05-28 |
2006-03-01 |
Virco Bvba |
Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
|
|
WO2002022781A2
(en)
*
|
2000-09-15 |
2002-03-21 |
Virologic, Inc. |
Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
|
|
AU2002226316B2
(en)
|
2000-10-20 |
2008-06-26 |
Virco Bvba |
Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
|
|
AU1234402A
(en)
*
|
2000-10-20 |
2002-04-29 |
Virco Nv |
Establishment of biological cut-off values for predicting resistance to therapy
|
|
US7247439B1
(en)
|
2001-06-04 |
2007-07-24 |
Monogram Biosciences, Inc. |
Method of evaluating a patient antibody response to envelope proteins of a virus
|
|
US7097970B2
(en)
|
2001-06-04 |
2006-08-29 |
Monogram Biosciences, Inc. |
Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs
|
|
EP1446498B1
(en)
|
2001-11-08 |
2008-03-12 |
Tibotec Pharmaceuticals Ltd. |
Protease assay for therapeutic drug monitoring
|
|
CA2490862A1
(en)
|
2002-07-01 |
2004-01-08 |
Tibotec Pharmaceuticals Ltd. |
Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
|
|
WO2004003223A2
(en)
|
2002-07-01 |
2004-01-08 |
Tibotec Pharmaceuticals Ltd. |
New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
|
|
DE20218008U1
(de)
|
2002-11-21 |
2003-03-06 |
FESTO AG & Co., 73734 Esslingen |
Anordnung von mehreren Handhabungsvorrichtungen
|
|
US8603736B2
(en)
|
2004-06-07 |
2013-12-10 |
Monogram Biosciences, Inc. |
Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
|
|
EP2522757A1
(en)
|
2005-02-18 |
2012-11-14 |
Monogram BioSciences, Inc. |
Methods and compositions for determining anti-HIV drug susceptibility and replication capacity of HIV
|
|
WO2006089045A2
(en)
|
2005-02-18 |
2006-08-24 |
Monogram Biosciences, Inc. |
Methods and compositions for determining hypersusceptibility of hiv-1 to non-nucleoside reverse transcriptase inhibitors
|
|
EP2458019A3
(en)
|
2005-05-27 |
2012-07-25 |
Monogram BioSciences, Inc. |
Methods and compositions for determining resistance of HIV-1 to protease inhibitors
|
|
WO2006133267A2
(en)
|
2005-06-06 |
2006-12-14 |
Monogram Biosciences, Inc. |
Methods and compositions for determining altered susceptibility of hiv-1 to anti-hiv drugs
|
|
US9506121B2
(en)
|
2005-06-06 |
2016-11-29 |
Monogram Biosciences, Inc. |
Methods for determining resistance or susceptibility to HIV entry inhibitors
|
|
US8114585B2
(en)
|
2006-06-13 |
2012-02-14 |
Monogram Biosciences, Inc. |
Method for determining human immunodeficiency virus (HIV) coreceptor utilization by examining gp41 molecular determinants
|
|
ES2639568T3
(es)
*
|
2007-01-23 |
2017-10-27 |
Janssen Pharmaceutica Nv |
Método para diseñar un régimen farmacológico para pacientes infectados con el VIH
|
|
WO2008106115A2
(en)
|
2007-02-26 |
2008-09-04 |
Monogram Biosciences, Inc. |
Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy
|
|
WO2018030534A1
(ja)
*
|
2016-08-10 |
2018-02-15 |
国立研究開発法人理化学研究所 |
Ｂ型肝炎治療用組成物、及びｂ型肝炎ウイルスの複製活性の評価方法
|
|
RU2646472C1
(ru)
*
|
2016-10-07 |
2018-03-05 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации |
Способ оценки эффективности терапии инфекции вызванной вирусом герпеса человека 6 типа у детей
|
|
WO2018126042A1
(en)
*
|
2016-12-29 |
2018-07-05 |
Virongy L.L.C. |
Retro- and lenti-hbv hybrid vectors and constructs
|
|
CN109722465B
(zh)
*
|
2019-01-07 |
2022-02-01 |
福建省疾病预防控制中心(福建省健康教育促进中心、福建省卫生检验检测中心) |
一种hiv耐药检测载体和构建方法
|
|
JP7773731B2
(ja)
*
|
2020-06-24 |
2025-11-20 |
シァメン・ユニヴァーシティ |
薬物スクリーニングモデル及びＨＢＶ ｃｃｃＤＮＡを標的化する方法
|